Citation Tools
Late breaking abstracts
Ovarian cancer
1195 Results of NSGO-OV-UMB1/ENGOT-OV30 study: a phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 1195 Results of NSGO-OV-UMB1/ENGOT-OV30 study: a phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)